CCCC C4 Therapeutics

C4 Therapeutics to Present at Upcoming Investor Conferences

C4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET
  • Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at . Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.

About C4 Therapeutics

C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit .



Investor & Media Contact
Kendra Adams
SVP, Communications & Investor Relations
EN
12/05/2021

Underlying

CCCCC4 Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agre...

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell m...

October 1, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Sup...

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations ...

September 20, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeuti...

September 4, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide ...

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting C4T to Host Webcast on September 20, 2025 at 3 pm ET WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Rece...

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which ...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch